Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10821556 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL21348763 | 0.82 | FADS1 (0.52) | SMN1; SMN2MEN1KMT2AALDH1A1RXFP1 | |
| SCHEMBL1078326 | 0.82 | RAB9A (0.55) | SMN1; SMN2ALDH1A1MAPTKDM4ENPC1 | |
| SCHEMBL1079994 | 0.82 | POLB (0.56) | SMN1; SMN2KMT2AALDH1A1KDM4ENPC1 | |
| SCHEMBL29723905 | 0.78 | KDR (0.72) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL30643208 | 0.78 | KDR (0.72) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL259238 | 0.78 | KDR (0.72) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL22362615 | 0.78 | F2R (0.63) | KMT2ARXFP1NPC1RAB9A | |
| SCHEMBL21348779 | 0.76 | SMN1; SMN2 (0.59) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL17279781 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009475-A1 | ROCK2 INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-02 | — | — | WO | disclosed |
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2019-09-12 | — | — | US | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | SMN1; SMN2 4764/4885MEN1 3330/4885KMT2A 1722/4885 |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, TNK2 | SMN1; SMN2 4283/4885MEN1 3494/4885KMT2A 1854/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | SMN1; SMN2 4764/4885MEN1 3330/4885KMT2A 1722/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | SMN1; SMN2 4764/4885MEN1 3330/4885KMT2A 1722/4885 |
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, TNK2 | SMN1; SMN2 4283/4885MEN1 3494/4885KMT2A 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.